皮肤软组织婴幼儿血管瘤药物治疗回顾及进展  

Review and progress of drug therapy for infantile hemangioma of skin and soft tissue

作　　者：雷世泽 石青梅[2] 陈星帆 雷少榕[2] Lei Shize;Shi Qingmei;Chen Xingfan;Lei Shaorong(Department of Environmental Engineering,School of Metallurgy and Environment,Central South University,Changsha 410200,China;Department of Plastic and Cosmetic Surgery,Xiangya Hospital,Cen-tral South University,Changsha 410008,China)

机构地区：[1]中南大学冶金与环境学院环境工程系,长沙410200 [2]中南大学湘雅医院整形美容外科,长沙410008

出　　处：《中国医师杂志》2018年第8期1278-1280,F0003,共4页Journal of Chinese Physician

摘　　要：本文总结皮肤软组织婴幼儿血管瘤的药物治疗方案。回顾性分析文献,总结β-受体阻滞剂、糖皮质激素、博来霉素及咪喹莫特等药物的作用机制、使用方法及有效率和不良反应情况,分析合理的选择方案。β-受体阻滞剂作为口服及外用有着较高的有效率及很少的不良反应,可以作为婴幼儿血管瘤一线用药;咪喹莫特外用及糖皮质激素、博来霉素注射治疗有着良好的有效率及一定潜在的不良反应,可作为替代治疗方案用于婴幼儿血管瘤治疗。This article summarizes the pharmacological treatment of infantile hemangioma in soft tissue. We aim to review the literature and summarize the mechanisms, methods, efficiency and adverse re- actions of beta blockers, glucocorticoids, bleomycin and imiquimott, and to analyze the rational options. Beta blockers, as oral and external use, have high efficiency and few side effects, and can be used as a first - line medication for infantile hemangiomas. Imiquimod external use and topical glucocorticoid and bleomy- tin injection have good efficacy and potential adverse reactions. They can be used as an alternative treatment for infantile hemangioma.

关 键 词：血管瘤/药物疗法 皮肤肿瘤/药物疗法 婴儿 综述 

分 类 号：R732.2[医药卫生—肿瘤]